TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Refining and Pilot Testing Social Networks for Encouraging Healthy Behaviors: The Social Pounds Off Digitally (Social POD) Study
Brief Summary: Smartphones have the capability to monitor health-related behaviors (exercise, diet, etc.) and provide social support which has the potential to play a powerful role in health promotion. The objective of this study is to refine and pilot test the Social POD app for personalized health monitoring and interaction founded on a combination of social networks, recommender systems, motivational research, and health behavior theory. The aim of our proposed project is to conduct a 3-month pilot RCT among overweight and obese adults (N=150) comparing a theory-based podcast (TBP) plus self-monitoring using a commercially-available calorie and weight tracking app (current most popular diet self-monitoring method) versus TBP plus self-monitoring and social support/incentive points for participating with the Social POD app (TBP+Social POD).


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Use of PDA + support to reduce weight and pain | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: MOVE! level 2 group weight loss counseling | Intervention Type: BEHAVIORAL; Name: Use of PDA + support to reduce weight and pain; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: MOVE! level 2 group weight loss counseling; Assigned to Arm(s): Arm 2
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Device: Smartphone with APP, Behavioral: Counseling on lifestyles | Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Counseling on lifestyles | Intervention Type: DEVICE; Name: Smartphone with APP; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: Counseling on lifestyles; Assigned to Arm(s): Intervention group, Lifestyle counseling
C: Arm Label: Group Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Counseling | Arm Label: Individual Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Counseling | Arm Label: Smartphone Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Counseling | Intervention Type: BEHAVIORAL; Name: Lifestyle Counseling; Assigned to Arm(s): Group Treatment, Individual Treatment, Smartphone Treatment
D: Arm Label: Theory-based podcast; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Podcast + mobile diet app | Arm Label: Theory-based podcast + Social POD; Type: EXPERIMENTAL; Interventions: Behavioral: Podcast + theory-based mobile diet app | Intervention Type: BEHAVIORAL; Name: Podcast + mobile diet app; Assigned to Arm(s): Theory-based podcast | Intervention Type: BEHAVIORAL; Name: Podcast + theory-based mobile diet app; Assigned to Arm(s): Theory-based podcast + Social POD

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Isotonic Solution Administration Logistical Testing: Pilot Study for the Isotonic Solutions and Major Adverse Renal Events Trial
Brief Summary: The administration of intravenous crystalloids is ubiquitous in the care of the critically ill. Commonly available crystalloid solutions contain a broad spectrum of electrolyte compositions including a range of chloride concentrations. Recent studies of associated higher fluid chloride content with acute kidney injury and mortality but no large, randomized trials have been conducted. In preparation for a large, cluster-randomized, multiple-crossover trial comparing 0.9% sodium chloride to physiologically-balanced isotonic crystalloids (Lactated Ringers or Plasmalyte-A) in intensive care unit patients, this pilot study will enroll all patients admitted to the medical intensive care unit at a single tertiary center for a sixth month period. The primary objective will be to test the ability of an electronic order entry tool to ensure administration of assigned study fluid or record contraindications to assigned study fluid. The pilot study will also demonstrate the feasibility of collecting demographic, severity of illness, fluid management, vital sign, laboratory, acute kidney injury and renal replacement therapy, and outcome data in an automated, electronic fashion.


Options:
A: Arm Label: 0.9% sodium chloride; Type: ACTIVE_COMPARATOR; Interventions: Other: 0.9% sodium chloride | Arm Label: Physiologically balanced fluid; Type: ACTIVE_COMPARATOR; Interventions: Other: Physiologically balanced fluid | Intervention Type: OTHER; Name: 0.9% sodium chloride; Assigned to Arm(s): 0.9% sodium chloride | Intervention Type: OTHER; Name: Physiologically balanced fluid; Assigned to Arm(s): Physiologically balanced fluid
B: Arm Label: Lactated ringers solution; Type: EXPERIMENTAL; Interventions: Drug: Lactated Ringer Solution | Arm Label: Normal saline solution; Type: EXPERIMENTAL; Interventions: Drug: Normal Saline 0.9% Infusion Solution Bag | Intervention Type: DRUG; Name: Lactated Ringer Solution; Assigned to Arm(s): Lactated ringers solution | Intervention Type: DRUG; Name: Normal Saline 0.9% Infusion Solution Bag; Assigned to Arm(s): Normal saline solution
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: use of a non balced fluid and of a macromolecular fluid | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: use of balanced crystalloids fluid and macromolecular fluid | Intervention Type: DRUG; Name: use of a non balced fluid and of a macromolecular fluid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: use of balanced crystalloids fluid and macromolecular fluid; Assigned to Arm(s): 2
D: Arm Label: multiple electrolyte solution; Type: EXPERIMENTAL; Interventions: Drug: multiple electrolyte solution | Arm Label: saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: multiple electrolyte solution; Assigned to Arm(s): multiple electrolyte solution | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Local Endometrial Injury on Pregnancy Outcomes During Ovulation Induction Cycles
Brief Summary: The aim of this study is to detect whether or not performing an endometrial sampling in the cycle preceding ovulation induction with clomiphene citrate can improve pregnancy outcomes in the next cycle.


Options:
A: Arm Label: Endometrial injury group; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial injury | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Procedure: Control group | Intervention Type: PROCEDURE; Name: Endometrial injury; Assigned to Arm(s): Endometrial injury group | Intervention Type: PROCEDURE; Name: Control group; Assigned to Arm(s): Control group
B: Arm Label: Pipelle Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Pipelle de Cornier | Arm Label: Explora group; Type: ACTIVE_COMPARATOR; Interventions: Device: Explora curette | Intervention Type: DEVICE; Name: Pipelle de Cornier; Assigned to Arm(s): Pipelle Group | Intervention Type: DEVICE; Name: Explora curette; Assigned to Arm(s): Explora group
C: Arm Label: Scrathcing; Type: EXPERIMENTAL; Interventions: Procedure: scratching | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: scratching | Intervention Type: PROCEDURE; Name: scratching; Assigned to Arm(s): Control, Scrathcing
D: Arm Label: clomiphene and endometrial sampling; Type: ACTIVE_COMPARATOR; Interventions: Device: endometrial sampling, Drug: clomiphene citrate | Arm Label: clomiphene citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: clomiphene citrate | Intervention Type: DEVICE; Name: endometrial sampling; Assigned to Arm(s): clomiphene and endometrial sampling | Intervention Type: DRUG; Name: clomiphene citrate; Assigned to Arm(s): clomiphene and endometrial sampling, clomiphene citrate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Local Endometrial Injury on Pregnancy Outcomes During Ovulation Induction Cycles
Brief Summary: The aim of this study is to detect whether or not performing an endometrial sampling in the cycle preceding ovulation induction with clomiphene citrate can improve pregnancy outcomes in the next cycle.


Options:
A: Arm Label: Pipelle Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Pipelle de Cornier | Arm Label: Explora group; Type: ACTIVE_COMPARATOR; Interventions: Device: Explora curette | Intervention Type: DEVICE; Name: Pipelle de Cornier; Assigned to Arm(s): Pipelle Group | Intervention Type: DEVICE; Name: Explora curette; Assigned to Arm(s): Explora group
B: Arm Label: Scrathcing; Type: EXPERIMENTAL; Interventions: Procedure: scratching | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: scratching | Intervention Type: PROCEDURE; Name: scratching; Assigned to Arm(s): Control, Scrathcing
C: Arm Label: Office hysteroscopy and endometrial snip; Type: EXPERIMENTAL; Interventions: Procedure: Office hysteroscopy and endometrial snip | Arm Label: Office hyteroscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Office hysteroscopy | Intervention Type: PROCEDURE; Name: Office hysteroscopy and endometrial snip; Assigned to Arm(s): Office hysteroscopy and endometrial snip | Intervention Type: PROCEDURE; Name: Office hysteroscopy; Assigned to Arm(s): Office hyteroscopy
D: Arm Label: clomiphene and endometrial sampling; Type: ACTIVE_COMPARATOR; Interventions: Device: endometrial sampling, Drug: clomiphene citrate | Arm Label: clomiphene citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: clomiphene citrate | Intervention Type: DEVICE; Name: endometrial sampling; Assigned to Arm(s): clomiphene and endometrial sampling | Intervention Type: DRUG; Name: clomiphene citrate; Assigned to Arm(s): clomiphene and endometrial sampling, clomiphene citrate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 and Ibrutinib (BIG) Followed by GA101 and Ibrutinib Maintenance in CLL Patients (CLL2-BIG Protocol)
Brief Summary: A prospective, open-label, multicenter Phase-II trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 and Ibrutinib followed by Ibrutinib and GA101 maintenance in CLL patients.


Options:
A: Arm Label: Bendamustine + GA101 + Ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: GA101, Drug: Ibrutinib | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib | Intervention Type: DRUG; Name: GA101; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib
B: Arm Label: Phase I, NHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: Phase I, CLL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 400/400 mg - Phase II, iNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1600/800 mg - Phase II, iNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 400/400 mg - Phase II, aNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1600/800 mg - Phase II, aNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1000/1000 mg - Phase II, CLL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: Retreated Participants; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): 1000/1000 mg - Phase II, CLL, 1600/800 mg - Phase II, aNHL, 1600/800 mg - Phase II, iNHL, 400/400 mg - Phase II, aNHL, 400/400 mg - Phase II, iNHL, Phase I, CLL, Phase I, NHL, Retreated Participants
C: Arm Label: Idelalisib + rituximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Idelalisib, Drug: Rituximab | Arm Label: Placebo + rituximab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab, Drug: Placebo to match idelalisib | Intervention Type: DRUG; Name: Idelalisib; Assigned to Arm(s): Idelalisib + rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Idelalisib + rituximab, Placebo + rituximab | Intervention Type: DRUG; Name: Placebo to match idelalisib; Assigned to Arm(s): Placebo + rituximab
D: Arm Label: Experimental: 1; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide | Arm Label: Placebo Comparator: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Experimental: 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator: 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Oral Health Among Tobacco Quitline Callers
Brief Summary: The current study will test the effectiveness of a multi-modal behavioral intervention (the Oral Health 4 Life program) targeted to smokers who are ready to quit smoking and seeking services through tobacco quitlines.

The investigators hypothesize that, compared to people in the control arm, participants in the enhanced intervention will:

1. Be more likely to quit smoking as evidenced by 7 day point prevalent abstinence rates at 6 month follow-up \[primary outcome\] and at 2 month follow-up \[secondary outcome\].
2. Be more likely to see a dental care professional in the past 6 months at 6 month follow-up \[primary outcome\].
3. Exhibit more positive change in relevant oral health knowledge/beliefs and attitudes (e.g., self-efficacy, motivation) that could influence future behavior change.


Options:
A: Arm Label: Usual Care Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Control | Arm Label: Enhanced Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Intervention | Intervention Type: BEHAVIORAL; Name: Usual Care Control; Assigned to Arm(s): Usual Care Control | Intervention Type: BEHAVIORAL; Name: Enhanced Intervention; Assigned to Arm(s): Enhanced Intervention
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: QA-DDS; Type: EXPERIMENTAL; Interventions: Behavioral: QA-DDS | Intervention Type: BEHAVIORAL; Name: QA-DDS; Assigned to Arm(s): QA-DDS
D: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Brief Summary: The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Tralokinumab Dose 1; Type: EXPERIMENTAL; Interventions: Biological: Tralokinumab Dose 1 | Arm Label: Tralokinumab Dose 2; Type: EXPERIMENTAL; Interventions: Biological: Tralokinumab Dose 2 | Arm Label: Tralokinumab Dose 3; Type: EXPERIMENTAL; Interventions: Biological: Tralokinumab Dose 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Tralokinumab Dose 1; Assigned to Arm(s): Tralokinumab Dose 1 | Intervention Type: BIOLOGICAL; Name: Tralokinumab Dose 2; Assigned to Arm(s): Tralokinumab Dose 2 | Intervention Type: BIOLOGICAL; Name: Tralokinumab Dose 3; Assigned to Arm(s): Tralokinumab Dose 3
B: Arm Label: MEDI9929 280 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI9929 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI9929; Assigned to Arm(s): MEDI9929 280 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group1; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group2; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group3; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group4; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group5; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331), Other: Placebo | Intervention Type: DRUG; Name: nemolizumab (CIM331); Assigned to Arm(s): Group1, Group2, Group3, Group4, Group5 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group5
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: REGN668 | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: REGN668 | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: REGN668 | Intervention Type: BIOLOGICAL; Name: REGN668; Assigned to Arm(s): Cohort 1 | Intervention Type: BIOLOGICAL; Name: REGN668; Assigned to Arm(s): Cohort 2 | Intervention Type: BIOLOGICAL; Name: REGN668; Assigned to Arm(s): Cohort 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Indigestible Carbohydrates in an Over-night Design as Means to Modulate Colonic Events, With Specific Focus on Metabolism and Satiety
Brief Summary: The experimental model is a semi-acute, over-night, study where the purpose is to evaluate food factors related to colonially derived regulation and satiety in healthy subjects.


Options:
A: Arm Label: xylitol wipe; Type: EXPERIMENTAL; Interventions: Dietary Supplement: xylitol wipe | Arm Label: placebo wipe; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo wipe | Intervention Type: DIETARY_SUPPLEMENT; Name: xylitol wipe; Assigned to Arm(s): xylitol wipe | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo wipe; Assigned to Arm(s): placebo wipe
B: Arm Label: + ind. CHO; Type: EXPERIMENTAL; Interventions: Other: High levels of indigestible carbohydrates | Arm Label: - ind. CHO; Type: EXPERIMENTAL; Interventions: Other: Low levels of indigestible carbohydrates | Intervention Type: OTHER; Name: High levels of indigestible carbohydrates; Assigned to Arm(s): + ind. CHO | Intervention Type: OTHER; Name: Low levels of indigestible carbohydrates; Assigned to Arm(s): - ind. CHO
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-support for exclusive breastfeeding | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer-support for exclusive breastfeeding; Assigned to Arm(s): Intervention
D: Arm Label: one-to-one dental health education; Type: ACTIVE_COMPARATOR; Interventions: Other: Dental health education | Arm Label: anticipatory guidance technique; Type: EXPERIMENTAL; Interventions: Other: Dental health education | Intervention Type: OTHER; Name: Dental health education; Assigned to Arm(s): anticipatory guidance technique, one-to-one dental health education

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Brief Summary: This is a Phase 3, randomized, double blind, placebo controlled, parallel group, multicenter study in people with cystic fibrosis (CF) who are homozygous for the F508del CF transmembrane conductance regulator (CFTR) gene mutation.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: VX-661 Plus Ivacaftor Combination Placebo, Drug: Ivacaftor placebo | Arm Label: VX-661/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-661 Plus Ivacaftor Combination, Drug: Ivacaftor | Intervention Type: DRUG; Name: VX-661 Plus Ivacaftor Combination; Assigned to Arm(s): VX-661/IVA | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): VX-661/IVA | Intervention Type: DRUG; Name: VX-661 Plus Ivacaftor Combination Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ivacaftor placebo; Assigned to Arm(s): Placebo
C: Arm Label: N91115 + Rifampin; Type: EXPERIMENTAL; Interventions: Drug: N91115, Drug: Rifampin | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): N91115 + Rifampin | Intervention Type: DRUG; Name: Rifampin; Assigned to Arm(s): N91115 + Rifampin
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-445/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-445/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: VX-445/TEZ/IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B